The authors said this is the first study to examine antihypertension nonadherence down to the county level. Recommendations include greater use of combination therapy to reduce pill counts for patients with multiple chronic conditions, and synchronizing pharmacy visits to avoid multiple trips.
One of the more frustrating challenges in healthcare is nonadherence—patients who see the doctor but don’t take their medication as prescribed. For a variety of reasons, nonadherence rates are high among patients being treated for hypertension, but rates are not uniform, according to a new CDC report.
Nonadherence among those being treated for hypertension is troubling, since cardiovascular disease is the leading cause of death in the United States; hypertension affects 70% of those age 65 and older, according to the authors. Yet, data released Tuesday by the CDC, based on claims from Medicare Part D, found that 26.3% of patients prescribed medication were nonadherent in 2014, which means these patients were not taking their drugs at least 80% of the time.
The study found wide disparities among groups: whites had nonadherence rates of 24.3% and for Asians and Pacific Islanders, the rate was 26.3%. The nonadherence rate was 33.8% among Hispanics, 35.7% among African Americans, and 38.8% among Native Americans. Being poor increased nonadherence, with the rate at 32.1% among those with a low-income subsidy and 25.4% among those with no subsidy.
Geography also played a role. Counties with the highest nonadherence rates were clustered in the Southeastern United States, but there were also clusters in New Mexico and Arizona, Northern Alaska, and the District of Columbia, which had a rate of 33.7%. The lowest rates of nonadherence were seen in North Dakota (18.7%), followed by Wisconsin (18.8) and Minnesota (18.9%). This geographic divide was noted by the study’s authors, who made several recommendations:
The authors recognized that the cost of co-payments could be a factor, and CMS has taken steps to start phasing out the “donut hole,” which has been shown to cause some beneficiaries to stop taking medications as prescribed once they hit the coverage gap limit.
The study had several limitations: it may have overestimated those patients who switched therapies based on a doctor’s recommendations, but it could have underestimated those who are prescribed therapy but do not initiate treatment. There are also some patients who buy low-cost generics outside the prescription drug plan and would not show up in the data.
Still, this was the first study to examine geographic variation in antihypertension nonadherence down to the county level, the authors noted.
“Strategies to improve adherence range from individual patient engagement and intervention to systematic health systems changes, and coordinated approaches are important to improving adherence and the cardiovascular health of this population,” the authors wrote.
Reference
Ritchey M, Chang A, Powers C, et al. Vital signs: disparities in antihypertensive medication nonadherence among Medicare Part D beneficiaries—United States, 2014 [published online September 13, 2016]. Morb Mortal Wkly Rep. DOI: http://dx.doi.org/10.15585/mmwr.mm6536e1
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More